TP53 and acute myeloid leukemia: Fewer patients with MDS with mutated TP53 (8.7%, ICC), MDS/AML with mutated TP53 (8.1%, ICC), or MDS-biTP53 (10.9%, WHO-2022 criteria) underwent HSCT compared to those with other subtypes of MDS/AML, MDS-EB/IB, and MDS-f, despite being at a higher risk (Supplementary Table 3 and Table 2).